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ARTICLE
Global distribution of the most prevalent deletions
causing hypotonia–cystinuria syndrome
Kevin Martens1,2, Inge Heulens1, Sandra Meulemans1, Marco Zaffanello3, David Tilstra4,
Frederik J Hes5, Raoul Rooman6, Inge Franc¸ois7, Francis de Zegher7, Jaak Jaeken7,
Gert Matthijs2 and John WM Creemers*,1
1Laboratory for Biochemical Neuro-endocrinology, Department for Human Genetics, University of Leuven and Flanders
Interuniversity Institute for Biotechnology, Gent, Belgium; 2Laboratory for Molecular Diagnosis, Department for Human
Genetics, University of Leuven, Leuven, Belgium; 3Department of Mother and Child, Biology-Genetics, Section
of Paediatrics, University of Verona, Verona, Italy; 4CentraCare Clinic, St Cloud, MN, USA; 5Department of Clinical
Genetics, Leiden University Medical Centre, Leiden, The Netherlands; 6Department of Pediatrics, Antwerp University
Hospital, Antwerp, Belgium; 7Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium
Hypotonia–cystinuria syndrome (HCS) is a recessive disorder caused by microdeletions of SLC3A1 and
PREPL on chromosome 2p21. Patients present with generalized hypotonia at birth, failure to thrive, growth
retardation and cystinuria type I. While the initially described HCS families live in small regions in Belgium
and France, we have now identified HCS alleles in patients and carriers from the Netherlands, Italy, Canada
and United States of America. Surprisingly, among the nine deletions detected in those patients, only one
novel deletion was found. Furthermore, one previously described deletion was found six times, another
twice. Finally, we have investigated the frequency of both deletions using a random Belgian cohort. Given
the global occurrence, HCS should be considered in the differential diagnosis of neonatal hypotonia.
European Journal of Human Genetics (2007) 15, 1029–1033; doi:10.1038/sj.ejhg.5201881; published online 20 June 2007
Keywords: PREPL; SLC3A1; hypotonia; cystinuria; oligopeptidase; growth retardation
Introduction
The hypotonia–cystinuria syndrome (HCS; MIM 606407)
is a recessive congenital disorder characterized by general-
ized hypotonia at birth, failure to thrive, growth retarda-
tion and cystinuria type I.1,2 Recently, the genetic defect
underlying this syndrome has been characterized in nine
families.1 The disease is due to microdeletions that disrupt
two genes on chromosome 2p21, SLC3A1 and PREPL. As
mutations in SLC3A1 cause isolated cystinuria type I and
the flanking genes are normally expressed, the extended
phenotype can be attributed to PREPL.1
A larger deletion of 179 kb at this locus has previously
been reported,3,4 which causes the recessive 2p21 deletion
syndrome. At least four genes (SLC3A1, PREPL, PPM1B and
C2orf34) are deleted, resulting in a much more severe
phenotype. A detailed comparison between the two
syndromes has been published.5
At least three additional deletions involving PREPL have
been reported in patients with isolated cystinuria type I.
However, they were not fully characterized.6 – 8 Finally, one
sporadic case with HCS symptoms, accompanied with a
mitochondrial respiratory chain defect has been reported.
Molecular analysis of the SLC3A1/PREPL locus was sug-
gested but not performed.9
This report focuses on the molecular analysis of four new
HCS families, including two previously described cases.
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Finally, the frequency of the most prevalent deletions




Material from family 10 (University Hospitals Leuven,
Belgium), family 11 (University Medical Centre Leiden,
The Netherlands) and family 12 (CentraCare Clinic,
St Cloud, MN, USA) was sent for molecular diagnosis for
the SLC3A1/PREPL locus. DNA samples for family 13
(University of Verona, Italy) and family 14 (McGill
University, Montreal, Canada) were obtained upon request.
As a random population, we used the CAREGENE10 cohort.
Quantitative PCR
Quantitative PCR was performed using qPCR Master Mix
for SYBR Green I detection and fluorescein as internal
standard (Eurogentec, Seraing, Belgium) on the MyIQ
system (Bio-Rad, Nazareth-Eke, Belgium), in accordance
with the manufacturer’s guidelines. Primers were developed
with Primer Express software (Applied Biosystems, Nieu-
werkerk a/d IJssel, The Netherlands). The relative number of
alleles were calculated using the Livak (2DDCt ) method.11
An amplicon within the p53 gene was used as reference.
Junction fragment PCR and sequencing
PCR products were amplified using 150 ng of genomic
DNA, by the use of the Advantage 2 PCR kit (Clontech,
Mountain View, CA, USA). Junction fragments were
purified with the Montage PCR Centrifugal Filter Device
(Millipore, Billerica, MA, USA) before sequencing (Bigdye
Terminator v3.1, Applied Biosystems) on the ABI3130
system (Applied Biosystems). Primers used for amplifying
deletions A and B have been described.1 Primers for
deletion E are 50-TTGCTCCAAAAGTTCCTAACCAA-30 and
50-TTCTGTGTTGAGGTTGCACTCC-30.
Haplotype analysis
Genotypes of microsatellites and single nucleotide poly-
morphisms (SNP) were determined as described.1
Results
The clinical and endocrinological data on the patients are
similar to those reported earlier.1 Details are listed in Table 1.
In summary, the clinical picture is characterized by neonatal
and infantile hypotonia, and anorexia, often necessitating
nasogastric tube feeding or gastrostomy. Some dysmorphy is
present, particularly dolichocephaly and ptosis of the
eyelids, as well as a striking nasal speech. Anorexia and
hypotonia ameliorate with age, but gradually growth
velocity decreases due to IGF-1 insufficiency. Patients
respond well to growth hormone treatment. Electromyo-
graphy and brain magnetic resonance imaging are normal,
when performed. In addition, patients have classical
cystinuria type I causing nephrolithiasis at variable ages.
The presence or absence of different exons of SLC3A1
and PREPL was determined in patients and parents (when
Table 1 Clinical and endocrinological data on the patients
Family 10 Family 11 Family 12 Family 13
Actual age (years) 16 34/12 9 15
Sex M M M F
Birth weight (g) 1220 3185 3205 3660
Birth length (cm) 38 NI 44 50
Gestational age (weeks) 31 40 40 40
Infantile hypotonia + + + +
Infantile anorexia + + + +
Nasogastric tube feeding +  + +
Gastrostomy   + 
Dysmorphy Dolichocephaly Deep sunken eyes Dolichocephaly, eyelid ptosis
and tented upper lip

Nasal speech +  + +
Unsupported walking from (m) 18 23 14 14
Special school  NI + 
Growth retardation +  + +
From age (years) 1–2 NA 7 2.5
Growth hormone (basal/peak) 2.4/31 mU/ml NI NI 1.2 /10.2 mU/ml
IGF-1 3 SD NI NI 3 SD
Growth hormone treatment Yes NA Yes No
Start of puberty (years) 14 NA  12
Age of first symptomatic
nephrolithiasis
7 years (coral stone) No lithiasis yet No lithiasis yet No lithiasis yet
Electromyography Normal  Normal NI
Brain CT/MRI Normal MRI  Normal MRI Normal MRI
NI, no information; NA, not applicable
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available) using quantitative PCR. In families 11 and 13,
the boundaries for both deleted alleles were located in
intron 1 of SLC3A1 and intron 1 of PREPL. As the same
fragments were deleted in the previously described dele-
tion B,1 we performed a junction fragment PCR specific for
this deletion followed by sequencing of the amplicons
(Figure 1). Both patients are homozygous for deletion B,
therefore confirming the diagnosis of HCS. The patient in
family 10 is compound heterozygous for two deletions, one
identical to deletion B, the other extending from exon 10
in SLC3A1 to exon 2 in PREPL-like deletion A from Jaeken
et al.1 Junction fragment PCR and sequencing confirmed
that the second allele is indeed deletion A (Figure 1). The
patient in family 12 showed a homozygous loss from exon
10 in SLC3A1 to exon 2 in PREPL. Junction fragment PCR
and sequencing confirmed that the paternal allele is again
deletion A. The proximal boundary of the deletion on the
maternal chromosome is located in intron 1 of SLC3A1,
whereas the distal break point is located between 45 and
50 kb upstream of PREPL (Figures 1 and 2). Sequencing of
the junction fragment indicated that the deletion was
127 kb in size, with the distal break point located in intron
3 of C2orf34, the gene flanking PREPL. This is a novel allele
(deletion E) involved in HCS.
The patient in family 14 (patient 936 in Saadi et al6) has
isolated cystinuria type I, and has previously been
Figure 1 Genetic analysis of the HCS patients. (A) Quantitative PCR analysis on genomic DNA of HCS patients. Only relevant amplicons are shown.
(B) Junction fragments spanning the break point in patients and parents (when available). , negative control; P, patient; M, mother; F, father.
(C) Genotype of the patients.
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described as compound heterozygous for two deletions
involving SLC3A1. The deletion on the paternal allele had
been shown to extend from exon 1 to exon 7 of SLC3A1,
whereas the deletion on the maternal allele starts in intron
1 of SLC3A1 and extends beyond exon 10. We have now
determined the exact break points on the latter deletion.
Quantitative PCR analysis revealed that the proximal
boundary was located in intron 1 of SLC3A1, whereas the
distal break point was localized in intron 2 of PREPL. Again,
this pointed toward the presence of deletion B (Figure 1).
The different deletion alleles were haplotyped using
microsatellites and SNPs. Only family 10 showed a partially
conserved ancestral haplotype for deletion A (Figure 3).
SNPs genotyped in families 11–13 identified the same
alleles as present in the ancestral haplotype of deletion B;
however, the genotypes for families 11 and 13 were not
informative. The SNP data for family 10 could not be
obtained due to a lack of parental DNA (data not shown).
Because of the high incidence of deletions A and B, we
have screened a random Belgian cohort for the presence of
these deletions. We found 1 allele with deletion A and 1
allele with deletion B in a total of 936 random samples
(1872 chromosomes). This leads to an allele frequency
estimate for deletions A or B between 1/333 and 1/7700
(binomial distribution; 95% confidence interval).
Discussion
HCS was initially described in nine families living in
Belgium and France. On 18 independent chromosomes,
only four different deletions (deletions A–D) were found.
Figure 2 The 2p21 locus. (a) Genomic organization of the 2p21 locus. The flanking microsatellite markers used in the haplotype analysis are
indicated with their genomic coordinates. (b) Schematic representation of the deletions detected in the novel HCS families, presented here. Deletions
(a and b) have previously been described,1 whereas deletion E represents a new allele. Sequences flanking the break points are shown and are
numbered in accordance with the numbering in the database (Homo sapiens, build 36; http://www.ncbi.nlm.nih.gov/).
Figure 3 (A and B) Haplotype analysis for deletion. Completely conserved haplotypes are shaded dark gray, partially conserved haplotypes are
shaded light gray. Dashed lines indicate the break point. Note ‘a’ phase unknown.
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The frequency of deletions A and B was 4/18 and 11/18,
respectively, due to founder effects.1 In the four novel HCS
families and the one carrier of a HCS allele described here,
the frequency of deletions A and B were 2/9 and 6/9,
respectively. The allele frequencies of deletions A or B in a
random Belgian cohort were estimated between 1/333 and
1/7700.
Deletions A and B are globally distributed, as they were
found in patients from The Netherlands, Italy, Canada and
the United States America. However, the ancestral haplo-
types of the microsatellite markers flanking the break
points were completely decayed in these families, indicat-
ing that the deletions are old. However, it cannot be
excluded that a genetic mechanism is promoting deletions
in this region. If this is the case, however, it is remarkable
that the break points are exactly the same.
The patient in family 12 appeared to be compound
heterozygous for deletions A and E, the latter being a novel
deletion involved in HCS. This deletion does not only
disrupt the coding region of SLC3A1 and PREPL, but also of
C2orf34. C2orf34 has a putative methyltransferase domain,
but its function has not yet been described. It is, however,
not expected that a loss of one allele is modulating the
phenotype in this HCS patient, because the mother
showed no phenotype that might be due to the loss of
one allele of C2orf34.
Unexpected results were obtained for family 13. The
proband in this family showed all HCS symptoms,
accompanied with a mitochondrial respiratory chain
defect. As a mitochondrial respiratory chain defect was
also observed in the 2p21 deletion syndrome,3 one might
have expected that besides SLC3A1 and PREPL, at least one
other gene (PPM1B or C2orf133) was involved. However,
this patient is homozygous for deletion B, and therefore
her genotype is identical to some of the previously
published patients. She has been the only HCS patient
with a reported respiratory chain defect. This brings up an
intriguing question about the cause of the respiratory
chain defect in this patient. A possible explanation could
be the presence of variations in modifier genes, either in cis
or in trans, yet to be discovered. Currently, in-depth
analysis of mitochondrial respiratory chain function in
fibroblast cells from other HCS patients is being performed
to determine potential minor defects that might previously
have been overlooked.
Three deletions involving PREPL have been described in
patients with isolated cystinuria type I. We characterized
the deletion initially reported in Saadi et al.6 It turns out to
be the most frequent HCS allele, deletion B, only disrupt-
ing the coding region of SLC3A1 and PREPL. This leaves the
total of unique alleles where PREPL is deleted at six: five
deletions present in HCS and one causing the 2p21
deletion syndrome. Possibly, two other alleles exist, but
the break points have not been determined.7,8
In conclusion, HCS is a relatively homogenous syn-
drome, with common ancestral alleles found in different
populations. On the basis of the allele frequencies, this
disease will be rare (1/1 000 000 for an allele frequency of
1/1000); hence, our observations are compatible with a
founder effect in the regions from where the HCS patients
originate.
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